Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2020

Integral Molecular to work on coronavirus vaccine research

US-based biotechnology company Integral Molecular will leverage its technology platforms to identify Covid-19 vaccines and therapeutics.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

US-based biotechnology company Integral Molecular will leverage its technology platforms to identify Covid-19 vaccines and therapeutics.

Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array will be used to gain insights into the human immune response to the novel coronavirus.

The company will also utilise the platforms to discover cellular receptors that could provide information on the rapid spread of the virus.

Integral Molecular president Benjamin Doranz said: “Deep expertise in virology is at the core of Integral Molecular’s nearly 20-year history, including our contributions to discovering the receptor for HIV and other viruses.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“We have the ability to use our unique tools to help curb the spread of this deadly virus and have initiated research efforts on multiple fronts to aid in the global effort for a coronavirus vaccine.”

During previous emerging epidemics such as Ebola and Zika, Integral Molecular supported discovery efforts for vaccines and therapeutics.

The Shotgun Mutagenesis Epitope Mapping technology mapped more than 1,000 antibody binding sites to date, while the Membrane Proteome Array platform helped find various receptors used by viruses to infect cells.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU